Demant consensus picture midweek, analysts keep a buy tilt on the shares
24.06.2026 - 12:02:42 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-24, 11:59.
Demant (DK0010268440) draws a clear analyst consensus this week, with the stock traded on Nasdaq Copenhagen. The current focus is on how 19 covering analysts rate the shares and where they set their 12-month price targets, according to Investing.com data.
What the analyst data shows
According to a consensus overview for Demant on Nasdaq Copenhagen, 19 analysts currently cover the stock, with 12 issuing buy recommendations, 7 holds and none sells. This distribution leaves the overall rating at "Buy" and signals a predominantly positive stance from the sell-side community on the Danish hearing-care group.
The same consensus compilation points to an average 12-month price target of 251.1 Danish kroner for Demant, with the highest target at 280 kroner and the lowest at 210 kroner. These figures give a structured view of where analysts expect the shares to trade over a one-year horizon and how much dispersion exists between optimistic and more cautious houses.
How the targets compare with the market
The consensus data also implies that Demant is currently trading modestly above the average price target, resulting in a calculated potential downside of around 2.29 percent versus the 251.1 kroner mean estimate. For investors, this means that while most analysts maintain a buy stance, the upside implied by the average target is limited at present levels, making individual price-target changes worth monitoring.
Analyst sentiment on Demant can be set against other large hearing-care peers such as GN Store Nord and Sonova, which also attract broad coverage in Europe. In this context, Demant's buy-weighted recommendation distribution underscores its position as a core name in the listed hearing-aid segment, with consensus still supportive despite the modest implied downside from current prices.
Background and price data on Demant
Further articles and data on the Demant shares, including past earnings, guidance changes and sector comparisons, are available in the dedicated AD HOC NEWS topic section and via the company’s investor-relations page.
The product behind the stock
Demant generates most of its revenue from hearing healthcare, including Oticon-branded digital hearing aids and related audiology solutions sold through clinics and retail chains. The group also operates in communications equipment and diagnostic instruments, offering a diversified earnings base within sound and hearing technologies.
Where the stock trades today
Demant shares (DK0010268440) trade on Nasdaq Copenhagen, with the latest available consensus data referencing prices in Danish kroner and positioning the stock modestly above the 251.1-kroner average analyst target as of the current midweek session.
Key data on the Demant shares
- Company: Demant A/S
- ISIN: DK0010268440
- WKN: 893130
- Ticker: DEMANT
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-24, 09:50): 257.0 DKK
- Market cap: 118000000000 DKK (as of 2026-06-24)
- Sector / industry: Health Care - Medical Equipment & Supplies
- Index membership: OMX Copenhagen 25
- Next earnings date: 2026-08-15
This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data were obtained from sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a professional advisor before making investment decisions.
